Treatment of recurrent suprahyoid cervicofacial lymphangioma with intravenous cyclophosphamide.
Surgical resection of cervicofacial cystic hygromas and lymphangiomas rarely effects complete reduction because of severe anatomic restrictions. With prior knowledge of cyclophosphamide activity against lesions of this type, a formal trial of cyclophosphamide was initiated. Overall dose escalation therapy resulted in 50% reduction in mass without recurrence after cessation of therapy and with minimal and readily reversible toxicity. The favorable responses to cyclophosphamide in this study suggest that a prospective randomized trial should be initiated. Certainly, children who have airway and/or esophageal compromise who have failed surgical therapies should be considered for cyclophosphamide treatment.